Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies? | Haematologica
... versus-host disease while it did not affect the rate of chronic graft-versus-host disease. Although the authors speculate that ... Kröger N, Solano C, Wolschke C. Antilymphocyte Globulin for Prevention of chronic graft-versus-host disease. N Engl J Med. 2016 ... Finke J, Bethge WA, Schmoor C. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in ... Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone ...
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy | Haematologica
Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995; 268:1476-80. ... Adverse side effects, however, may occur and lead to severe autoimmunity or graft-versus-host disease (GvHD), emphasizing the ... of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease ... B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol. 2008; ...
CD56|sup|bright|/sup|CD16|sup|-|/sup| natural killer cells as an important regulatory mechanism in chronic graft-|I|versus|/i|...
Whangbo JS, Antin JH, Koreth J.. The role of regulatory T cells in graft-versus-host disease management. Expert Rev Hematol. ... Chronic graft-versus-host disease (cGvHD) is a major cause of morbidity after hematopoietic stem cell transplantation (HSCT). ... Spoerl S, Mathew NR, Bscheider M. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014; 123(24): ... Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic ...
Vol. 108 No. 1 (2023): January, 2023 | Haematologica
Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of ... The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease (1938 Online Views) Pedro Horna, ... Nearly 70 years later: the continued unraveling of Castleman disease (1268 Online Views) Frits van Rhee ... The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease Pedro Horna et al. ...
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation |...
Petersdorf EW, Malkki M, OHuigin C. High HLA-DP expression and graft-versus-host disease. N Engl J Med. 2015; 373(7):599-609. ... Relapse and graft-versus-host disease (GvHD) are the main impediments to the clinical success of allogeneic hematopoietic cell ... Petersdorf EW, Bengtsson M, De Santis D. Role of HLA-DP expression in graft-versus-host disease after unrelated donor ... Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after ...
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy | Haematologica
CD3 depletion would still be required in the haplo-identical setting to avoid graft-versus-host disease. As exp-NK cells from ... A) NOD/scid/IL2Rγnull-hu hosts bearing OPM2 tumors were dosed with 160×106 exp-NK (given by four i.v. injections 48 h apart) ... Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002; 100(6):1935-47. ... However, the prognosis remains poor in approximately 15% of patients who have aggressive disease best captured by a high-risk ...
Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute...
... and chronic graft-versus-host disease. Statistical analyses were performed using SPSS 18.0 (SPSS Inc, Chicago, IL) and Splus ... Patients characteristics and information regarding disease and transplant are summarized in Table 1. The previously published ...
Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease |...
The overall cumulative incidence of grade II-IV acute graft-versus-host disease (GvHD) was 16% (95%CI 13-18%) [group 1: 10% (95 ... Table 1.Patient, disease, donor and HSCT characteristics.*. Primary graft failure was reported in 2% of the patients in group 1 ... In the setting of non-malignant disease, where graft-versus-leukemia is not needed, an efficient GvHD prophylaxis strategy is ... Gardner K, Douiri A, Drasar E. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016; 128(10):1436- ...
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid...
... acute graft-versus-host disease (GvHD) grade II-IV and grade III-IV. A secondary analysis was planned to explore the optimal ... Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-3671. ... Even then, inflammation can be influenced by divergent pathways of infection, hepatic sources, the primary disease, or genetic ... Most subjects were Caucasian (95%), and received myeloablative regimens (72%). The primary disease indication was AML (80%), ...
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma ...
Patients previously treated with PI3K inhibitors, or those with evidence of graft-versus-host disease, active or past central ... progressive disease; PR: partial response; SD, stable disease. ... Most patients (73.6%) had stage III/IV disease at initial ... The PI3K/mTOR pathway is frequently activated in NHL and plays an important role in the pathogenesis of this disease.14 However ... Differential PI3K isoform expression levels have also been associated with different disease stages in NHL.23 For example, in ...